Notice to holders of the QIAGEN N.V. (the “Issuer”): 0.375% Senior Unsecured Convertible Notes due 2019 (the “2019 Notes”) – ISIN XS1046477235 0.875% Senior Unsecured Convertible Notes due 2021 (the “2021 Notes”) – ISIN XS1046477581 0.500% Senior Unsecured Convertible Notes due 2023 (the “2023 Notes”) – ISIN XS1682511818 1.000% Senior Unsecured Convertible Notes due 2024... Read more
ZEISS microscopes help uncover centuries old hidden secrets of human kidney stones Customer Story Knowledge Kidney stones are hard deposits made of minerals and salts that can form inside your kidneys. They have been ascribed no medical value at all, and doctors usually discard them right away. A research team led by Bruce Fouke, a... Read more
BILLERICA, Mass., Dec. 20, 2018 /PRNewswire/ — Bruker Corporation (NASDAQ: BRKR) has been advised that former board member, Mr. Joerg C. Laukien, has authorized a block sale of Bruker shares as part of his retirement planning and portfolio diversification. Joerg Laukien retired from the Bruker board of directors effective November 5, 2018. He is the brother... Read more
This article is translated from press release in Japanese for your convenience. Forward-Looking Statements Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management... Read more
FRANKLIN LAKES, N.J., Dec. 11, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the completion of an enterprise level cybersecurity assessment from UL. This independent assessment evaluates corporate cybersecurity programs and policies to ensure that all medical devices developed by a company are built with robust... Read more
To provide an optimal solution for blood collection, Greiner Bio-One has developed the new VACUETTE® SAFELINK Holder. This sterile tube holder provides a safe, needleless option for blood collection procedures from a female luer port. The VACUETTE® SAFELINK provides a secure luer lock connection, making this holder a safe and easy-to-use accessory for transfer of... Read more
Basel, 05 December 2018 Roche’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment At three years, 88.3% of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared... Read more
5 December 2018 HORIBA UK Ltd. is pleased to welcome back Dr. Simon FitzGerald to its Scientific team in the role of Technical Manager. He will lead the company’s team of application and product specialists to help further HORIBA’s position as a world-leading manufacturer of spectroscopic instrumentation. Dr. FitzGerald will also work closely with users... Read more
Basel, 03 December 2018 Roche’s Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors Nearly 77% of children receiving Hemlibra once weekly experienced zero treated bleeds Hemlibra once weekly reduced treated bleeds by 99% compared to prior bypassing agents in a prospective intra-patient... Read more
Basel, 03 December 2018 Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma Polatuzumab vedotin in combination with MabThera/Rituxan (rituximab) plus bendamustine more than doubled overall survival, compared to MabThera/Rituxan plus bendamustine alone in the phase Ib/II GO29365 study Polatuzumab vedotin has the potential to provide... Read more